Section 14: Hematologic Disorders

Section 14: Hematologic Disorders

The genetic inheritance pattern for hemophilia is:

A. Autosomal dominant

B. Autosomal recessive

C. X-linked

D. Genetic polymorphism

The answer is C.

The factor deficit in hemophilia B is:

A. Factor II

B. Factor VII

C. Factor VIII

D. Factor IX

The answer is D.

Which of the following is not considered a goal of Hemophilia therapy?

A. Prevent bleeding episodes

B. Prevent long term complications

C. Eradicate inhibitors

D. Arrest bleeding if it occurs

The answer is C.

Patients with severe hemophilia have ______% factor activity level.

A. <1%

B. 1-4%

C. 3-5%

D. >5%

The answer is A.

The first-line therapeutic approach to treating an active bleed in a patient with severe hemophilia without inhibitors is:

A. Plasma derived factor replacement

B. Recombinant factor replacement

C. Activated prothrombin complex concentrates (aPCCs)

D. Desmopressin

E. Anti-thrombolytic

The answer is B.

Which is a true statement regarding prophylaxis therapy for hemophilia?

A. Not recommended by any national organization

B. Recommended approach but optimal dosing and schedule is not well defined

C. Proven cost effective

D. Patient compliance is not a factor in overall outcome

The answer is B.

The most impactful therapeutic complication of therapy for hemophilia patients is:

A. Infection

B. Cost

C. Inhibitor formation